Sljedeći

Auto Play

The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma

2 Pogledi • 07/18/23
Udio
Ugraditi
administrator
administrator
Pretplatnici
0

Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.

Prikaži više
0 Komentari sort Poredaj po
Komentari na Facebooku

Sljedeći

Auto Play